SeqLL Inc. (SQL)
6.60
-0.16 (-2.37%)
At close: Jan 16, 2025, 9:00 PM
Company Description
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide.
The company designs, develops, and manufactures genetic analysis technologies.
It offers true single molecule sequencing (tSMS) platform, which offers a single molecule solution for DNA and RNA sequencing.
The company has a collaboration agreement with Bernstein Laboratory, Ting Laboratory, The Jackson Laboratory for Genomic Medicine, Weizmann Institute of Science, True Bearing Diagnostics, Inc., and Tetracore, Inc.
It serves academic and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations.
The company was founded in 2013 and is based in Billerica, Massachusetts.
SeqLL Inc.
| Country | United States |
| IPO Date | Aug 27, 2021 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Daniel Robert Jones |
Contact Details
Address: 3 Federal Street Billerica, Massachusetts United States | |
| Website | https://seqll.com |
Stock Details
| Ticker Symbol | SQL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001605888 |
| CUSIP Number | 81734C106 |
| ISIN Number | US81734C3043 |
| Employer ID | 46-5319744 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Daniel Robert Jones | Co-Founder, President, Chief Executive Officer & Chairman |
| Frances P. Scally | Chief Financial Officer & Secretary |
| John W. Kennedy | Chief Financial Officer & Sec. |
| Brian Paras | Chief Business Officer |
| Erik Volke | Director of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 10-K | Annual Report |
| Feb 28, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 424B3 | Filing |
| Jan 24, 2025 | S-4/A | [Amend] Filing |
| Jan 23, 2025 | S-4/A | [Amend] Filing |
| Jan 16, 2025 | SCHEDULE 13D | Filing |
| Jan 16, 2025 | SCHEDULE 13D | Filing |
| Jan 16, 2025 | SCHEDULE 13D | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 13, 2025 | SCHEDULE 13D | Filing |